Establishment and Validation of the Detection of TERT Promoter Mutations by Human Gliomas U251 Cell Lines
Table 3
Correlations between clinicopathological characteristics and the status of TERTp mutations.
Total
TERTp
value
Mut
Wt
(%)
(%)
(%)
Sex
0.041
Male
84 (57.1)
40 (67.8)
44 (50.0)
Female
63 (42.9)
19 (32.2)
44 (50.0)
Age (years)
<0.001
<45
70 (47.6)
17 (28.8)
53 (60.2)
45-60
59 (40.1)
31 (52.5)
28 (31.8)
≥60
18 (12.2)
11 (18.6)
7 (8.0)
Tumor location
0.729
Frontal
91 (61.9)
38 (64.4)
53 (60.2)
Others
56 (38.1)
21 (35.6)
35 (39.8)
Histology
0.007
DA
37 (25.2)
8 (13.6)
29 (33.0)
AA
15 (10.2)
4 (6.8)
11 (12.5)
AO
24 (16.3)
16 (27.1)
8 (9.1)
OA
6 (4.1)
1 (1.7)
5 (5.7)
O
28 (19.0)
14 (23.7)
14 (15.9)
GBMs
37 (25.2)
16 (27.1)
21 (23.9)
Pathologic stage
0.338
Grade II-III
109 (74.1)
41 (69.5)
68 (77.3)
Grade IV
38 (25.9)
18 (30.5)
20 (22.7)
Ki-67
0.392
<15%
89 (60.5)
33 (55.9)
56 (63.6)
≥15%
58 (39.5)
26 (44.1)
32 (36.4)
IDH gene
0.312
Mutation
76 (51.7)
34 (57.6)
42 (47.7)
Wild type
71 (48.3)
25 (42.4)
46 (52.3)
MGMT promoter
0.088
Methylated
108 (73.5)
48 (81.4)
60 (68.2)
Unmethylated
39 (26.5)
11 (18.6)
28 (31.8)
TERTp: the promoter region of the telomerase reverse transcriptase gene; IDH: isocitrate dehydrogenase; MGMT: O6-methylguanine-DNA methyltransferase; Mut: mutation; Wt: wild-type; DA: diffuse astrocytoma; AA: anaplastic astrocytoma; AO: anaplastic oligodendroglioma; OA: oligoastrocytoma; O: oligodendroglioma; GBMs: glioblastomas. value was calculated by the Pearson chi-square test or the 2-tailed Fisher’s exact test. Statistically significant: .
